Xiwen Huang, PhD

Gilead Sciences, Inc.

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-512) Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre‑exposure Prophylaxis (PrEP): A Real-World Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-581) Racial/Ethnic Disparities of Renal Outcomes in People with HIV (PWH) on Tenofovir Alafenamide (TAF) Based Antiretroviral Treatment (ART) Regimens in the Real World
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT